Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Skin Cancer01:30

Skin Cancer

5.6K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.6K
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Brain Network Connectivity Predicts Survival in Diffuse Midline Glioma.

Cancer discovery·2026
Same journal

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

Cancer discovery·2026
Same journal

CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

Cancer discovery·2026
Same journal

CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

Cancer discovery·2026
Same journal

SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer.

Cancer discovery·2026
Same journal

Nonprofit Acquires Abandoned Leukemia Drug Supply.

Cancer discovery·2026

Related Experiment Video

Updated: Dec 23, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

Triple Therapy Better for Advanced Melanoma

    Cancer Discovery
    |April 30, 2020
    PubMed
    Summary

    Adding a PD-L1 inhibitor to targeted therapy significantly improved progression-free survival in advanced melanoma patients with BRAF V600 mutations. Combination therapy offers greater survival benefits than single treatments alone.

    Area of Science:

    • Oncology
    • Immunotherapy
    • Melanoma Research

    Background:

    • Advanced melanoma with BRAF V600 mutations presents a therapeutic challenge.
    • Targeted therapies like MEK-BRAF inhibitors show efficacy but often face resistance.
    • Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment.

    Purpose of the Study:

    • To evaluate the efficacy of combining a PD-L1 inhibitor with standard targeted therapy.
    • To assess the impact on progression-free survival (PFS) in untreated BRAF V600-positive advanced melanoma.
    • To compare the combination therapy's benefits against single-agent treatments.

    Main Methods:

    • A clinical study involving patients with untreated BRAF V600 mutation-positive advanced melanoma.
    • Administration of a PD-L1 inhibitor in combination with a standard targeted therapy (MEK-BRAF inhibition).

    More Related Videos

    A 3D Organotypic Melanoma Spheroid Skin Model
    08:49

    A 3D Organotypic Melanoma Spheroid Skin Model

    Published on: May 18, 2018

    16.4K
    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
    09:15

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

    Published on: February 24, 2023

    3.8K

    Related Experiment Videos

    Last Updated: Dec 23, 2025

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    27.7K
    A 3D Organotypic Melanoma Spheroid Skin Model
    08:49

    A 3D Organotypic Melanoma Spheroid Skin Model

    Published on: May 18, 2018

    16.4K
    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
    09:15

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

    Published on: February 24, 2023

    3.8K
  • Assessment of progression-free survival (PFS) as the primary endpoint.

    • Main Results:

    • The combination of PD-L1 inhibitor and targeted therapy resulted in significantly improved progression-free survival.
    • This combination demonstrated superior clinical benefits compared to MEK-BRAF inhibition alone.
    • The findings support the enhanced efficacy of dual blockade strategies in this patient population.

    Conclusions:

    • Combining PD-L1 inhibitors with MEK-BRAF targeted therapy offers significant survival advantages for advanced melanoma patients.
    • This combination strategy represents a promising therapeutic approach, outperforming monotherapies.
    • Further research is warranted to explore the long-term survival outcomes and potential synergistic mechanisms.